Boston Scientific, Nevro settle ongoing intellectual property litigations

This settlement concludes all of the existing litigations between Nevro and Boston Scientific, and includes a net payment from Boston Scientific to Nevro of $85 million.;

Published On 2022-08-02 09:56 GMT | Update On 2022-08-02 09:57 GMT

Redwood City: Nevro Corp. and Boston Scientific Corp. announced that they have reached a settlement in their ongoing intellectual property litigations that gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, and gives Nevro the freedom to operate using the features and capabilities embodied in its current line of products.

Nevro will grant Boston Scientific a worldwide, non-exclusive, non-transferable license to practice paresthesia-free therapy at frequencies below 1,500 Hz and a covenant not to sue for any features embodied in any current Boston Scientific products for frequencies below 1,500 Hz.

Boston Scientific also will grant Nevro a worldwide, non-exclusive, non-transferable license under Boston Scientific's asserted patent families and a covenant not to sue for any features embodied in any current Nevro products.

This settlement concludes all of the existing litigations between Nevro and Boston Scientific, and includes a net payment from Boston Scientific to Nevro of $85 million.

Headquartered in Redwood City, California, Nevro is a global medical device company. Nevro's comprehensive HFX spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic trunk and limb pain and painful diabetic neuropathy. Senza, Senza II, and Senza Omnia are the SCS systems that deliver Nevro's proprietary 10 kHz Therapy.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Boston Scientific, Nevro settle ongoing intellectual property litigations

This settlement concludes all of the existing litigations between Nevro and Boston Scientific, and includes a net payment from Boston Scientific to Nevro of $85 million.;

Similar News

Govt Amends Marketing Code for Medical Devices, Details

ICMR, CDSCO, Industry leaders emphasize collaboration, regulatory reforms to strengthen India's pharma leadership

GE HealthCare Revolution Vibe CT system gets USFDA clearance

India MedTech Expo 2025: DoP to hold second edition from 4th to 6th September

Minister calls for strong focus on RnD to produce affordable, high-quality medical devices

India making major strides towards self reliance in high end medical devices

AiMeD Flags Risks in GST Overhaul For Medical Devices, Seeks Balanced 5%-12% Tax Structure

Meril names Faisal Shah Mohammad as Business Head - Neurovascular